Human Platelet Senescence.
Annual summary rept. no. 2, 1 Jul 69-30 Jun 70,
NEW YORK UNIV MEDICAL CENTER N Y
Pagination or Media Count:
Se-75 Selenomethionine was used as a cohort label, in vivo, in 3 volunteer patients. Platelets were isolated on various days during the study and the heavy and light platelet populations is lated. Kinetic data revealed that young platelets, released early from the bone marrow, were the heavy-large platelets, released early from the bone marrow, were the heavy-large platelets which progressed with age to lighter-smaller platelets. The glycolytic enzymes of the Embden-Meyerhof pathway have been analyzed in heavy-large young and light-small older platelets. The enclosed table reveals the Km and Vmax for each enzyme for the total platelet population and the Vmax for the individual platelet populations. When Vmax of the total platelet population is compared to glycolytic flux glucose to lactate., the apparent rate-limiting enzymes for glycolysis are phosphofructokinase and glyceral-dehyde-3-P-dehydrogenase. Several Embden-Meyerhof enzymes decreased significantly with age hexokinase, phosphoglucomutase, phosphohexoseisomerase, phosphofructokinase, glyceral-dehyde-3-P-dehydrogenase, phosphoglyceromutase and lactic dehydrogenase. Since both phosphofructokinase and glyceraldehyde-3-P-dehydrogenase are also rate-limiting as well as significantly reduced with age--these two enzymes appear to be the critical enzymes in the modulation of in vivo human platelet senescence. Any attempt at preserving platelet viability on the self, might be directed towards stabilizing both of these enzymes.
- Anatomy and Physiology
- Medicine and Medical Research